← Corcept Therapeutics overview

Corcept Therapeutics vs Alnylam Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Corcept Therapeutics Incorporated (CORT)

Q3 2026
▲4

Corcept's earnings blowout and raised outlook lift the stock

  • Q2 results smash expectations, guidance raised Corcept reported second-quarter revenue of $256.1 million, up 31.7% from a year earlier and 21.6% above what analysts expected, with profit also beating. Management raised its 2026 revenue forecast to $1.1-$1.2 billion. A company beating expectations and raising its outlook makes investors pay more for the stock.

    This is the core new event driving the stock: a big earnings beat plus a raised full-year forecast.

  • New ovarian cancer drug Lifyorli starts selling Lifyorli, approved in March 2026 for platinum-resistant ovarian cancer, brought in $47.6 million in its first quarter on the market. A brand-new product generating real sales means the company is no longer relying on one drug, which supports a higher value for the stock.

    It shows a second revenue source actually selling, a new fact that supports the bull case.

  • Korlym keeps growing; second approval decision due Dec. 17 Korlym, the Cushing's syndrome drug, sold $373.5 million in the first half, up 6.2%. Corcept also resubmitted its application for relacorilant in hypercortisolism, which the FDA accepted with a decision expected by December 17, 2026 — a possible second use for its key drug.

    Ongoing Korlym growth plus a near-term FDA decision are the fundamental forces behind the stock.

  • Analysts sharply raise profit forecasts Over the past 60 days, the average analyst estimate for 2026 earnings per share jumped from 58 cents to $2.02, and for 2027 from $2.27 to $3.44. When expected profits rise this fast, the stock usually re-rates higher because it looks cheaper relative to those profits.

    Rising earnings estimates explain why the stock's valuation has moved up, not just the headline beat.

August 2026
▲4

Corcept's earnings blowout and raised outlook lift the stock

  • Q2 results smash expectations, guidance raised Corcept reported second-quarter revenue of $256.1 million, up 31.7% from a year earlier and 21.6% above what analysts expected, with profit also beating. Management raised its 2026 revenue forecast to $1.1-$1.2 billion. A company beating expectations and raising its outlook makes investors pay more for the stock.

    This is the core new event driving the stock: a big earnings beat plus a raised full-year forecast.

  • New ovarian cancer drug Lifyorli starts selling Lifyorli, approved in March 2026 for platinum-resistant ovarian cancer, brought in $47.6 million in its first quarter on the market. A brand-new product generating real sales means the company is no longer relying on one drug, which supports a higher value for the stock.

    It shows a second revenue source actually selling, a new fact that supports the bull case.

  • Korlym keeps growing; second approval decision due Dec. 17 Korlym, the Cushing's syndrome drug, sold $373.5 million in the first half, up 6.2%. Corcept also resubmitted its application for relacorilant in hypercortisolism, which the FDA accepted with a decision expected by December 17, 2026 — a possible second use for its key drug.

    Ongoing Korlym growth plus a near-term FDA decision are the fundamental forces behind the stock.

  • Analysts sharply raise profit forecasts Over the past 60 days, the average analyst estimate for 2026 earnings per share jumped from 58 cents to $2.02, and for 2027 from $2.27 to $3.44. When expected profits rise this fast, the stock usually re-rates higher because it looks cheaper relative to those profits.

    Rising earnings estimates explain why the stock's valuation has moved up, not just the headline beat.

Latest
▲4

Corcept's earnings blowout and raised outlook lift the stock

  • Q2 results smash expectations, guidance raised Corcept reported second-quarter revenue of $256.1 million, up 31.7% from a year earlier and 21.6% above what analysts expected, with profit also beating. Management raised its 2026 revenue forecast to $1.1-$1.2 billion. A company beating expectations and raising its outlook makes investors pay more for the stock.

    This is the core new event driving the stock: a big earnings beat plus a raised full-year forecast.

  • New ovarian cancer drug Lifyorli starts selling Lifyorli, approved in March 2026 for platinum-resistant ovarian cancer, brought in $47.6 million in its first quarter on the market. A brand-new product generating real sales means the company is no longer relying on one drug, which supports a higher value for the stock.

    It shows a second revenue source actually selling, a new fact that supports the bull case.

  • Korlym keeps growing; second approval decision due Dec. 17 Korlym, the Cushing's syndrome drug, sold $373.5 million in the first half, up 6.2%. Corcept also resubmitted its application for relacorilant in hypercortisolism, which the FDA accepted with a decision expected by December 17, 2026 — a possible second use for its key drug.

    Ongoing Korlym growth plus a near-term FDA decision are the fundamental forces behind the stock.

  • Analysts sharply raise profit forecasts Over the past 60 days, the average analyst estimate for 2026 earnings per share jumped from 58 cents to $2.02, and for 2027 from $2.27 to $3.44. When expected profits rise this fast, the stock usually re-rates higher because it looks cheaper relative to those profits.

    Rising earnings estimates explain why the stock's valuation has moved up, not just the headline beat.

Alnylam Pharmaceuticals Inc (ALNY)

Q3 2026
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

July 2026
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Latest
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Q2 2026
▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

June 2026
▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.